811 results about "Monocyte" patented technology

The invention belongs to the field of molecular biology and immunology, and particularly relates to an anti-CD3 nano antibody capable of activating the activity of T cells as well as a preparation method and application of the anti-CD3 nano antibody. The invention provides a preparation method of the anti-CD3 nano antibody. The preparation method comprises the following steps: constructing a CD3 plasmid and an overexpression cell line, and immunizing alpaca to obtain peripheral blood mononuclear cells (PBMC) of the alpaca; extracting RNA (Ribonucleic Acid) and carrying out reverse transcription to obtain cDNA; carrying out PCR amplification on the antibody gene segment and cloning the antibody gene segment to a phage display vector; and electrically transforming the vector into SS320 competent cells to obtain the nano antibody library. After two rounds of panning, detecting and screening an antibody clone capable of being combined with the CD3 protein through ELISA (Enzyme-Linked Immunosorbent Assay); an antibody sequence is selected through sequencing, and an antibody protein is expressed by using a mammalian cell high-throughput expression system; and then detecting and screening the antibody which is only specifically combined with the CD3. The method disclosed by the invention is simple, convenient and rapid to operate, and can be used for preparing active antibodies for treating potential tumors and proliferative diseases.

The invention discloses an antibacterial peptide and application thereof, and belongs to the technical field of biology. The antibacterial peptide with an inhibition effect on various clinically common pathogenic microorganisms is obtained, and the antibacterial peptide comprises gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, vibrio parahaemolyticus, salmonella gallinarum, salmonella typhimurium and enterobacter sakazakii, and gram-positive bacteria. The antibacterial peptide provided by the invention can be used as an antibacterial peptide, such as staphylococcus aureus, listeria monocytogenes and bacillus cereus, and the antibacterial peptide provided by the invention is novel in structure and easy to prepare.

The invention discloses a bacterial strain for degrading aspartame, a bacterial-algae symbiotic system and application of the bacterial strain and the bacterial-algae symbiotic system, the bacterial strain is corn sphingomonas zeae NCU J1, and the preservation number of the bacterial strain is CCTCC (China Center for Type Culture Collection) NO: M 20251462. And an algal-bacterial symbiotic system is constructed by adopting an oriented symbiotic combination of the corn sphingomonas NCU J1 and the chlorella sp. The corn sphingomonas NCU J1 can metabolize an artificial sweetening agent aspartame and degradation products thereof, metabolism complementation can be achieved through an algal-bacterial symbiotic interface, and bacteria preferentially promote aspartame to be subjected to photohydrolysis to generate degradation products such as diketopiperazine derivatives. The microalgae synchronously start isomerism enzymatic reaction to convert degradation products such as diketopiperazine derivatives into low-toxicity products, the risk of secondary pollution is reduced by 40% or above compared with that of a traditional physical and chemical method, 150 mg / L aspartame can be efficiently degraded within 2 days, generation of derivatives of aspartame can be greatly reduced, secondary pollution is reduced, and the method is suitable for industrial production. And the method has a good application prospect in the aspect of rapidly treating aspartame-containing wastewater.

The invention discloses a method for differentiating induced pluripotent stem cells into macrophages. The method comprises the following steps: S1, inducing pluripotent stem cells to form embryoid bodies; s2, differentiating the embryoid body into a monocyte with CD14 expression; s3, the mononuclear cells are differentiated into macrophages with CD14 / CD11b expression; and S4, polarizing the macrophages into M1 type macrophages and / or M2 type macrophages. According to the method for differentiating the induced pluripotent stem cells into the macrophages, the cells can be effectively induced to differentiate towards the macrophages, the induced pluripotent stem cells are subjected to directional differentiation culture in a short time to obtain the macrophages, and the generated macrophages express CD14 and CD11b and have remarkable phagocytic activity on yeast glycan. The method is of great significance to large-scale production of macrophages.

The invention belongs to the technical field of medicines, and particularly discloses application of niclosamide in preparation of a medicine for treating epididymis and testis fibrosis caused by bacterial infection. A UPEG-mouse epididymis / orchitis model is firstly constructed, a result shows that a monocyte subset highly expressed by S100a4 appears in a testis, the group of cells mainly express CD11b monocyte characteristics in the early stage when entering the testis, and the group of cells are partially converted into F4 / 80 + and alpha-SMA + fibroblast characteristics in the later stage. A myeloid macrophage knockout mouse is used for constructing a UPEG-epididymis / orchitis model, and the fibrosis degree of testis and epididymis is obviously reduced; a molecular mechanism shows that S100a4 can strengthen a TGF beta-STAT3 signal channel to promote the transformation of macrophages to fibroblasts, and niclosamide can inhibit the process. Mouse in-vivo experiment results show that niclosamide can obviously inhibit UPEG-mouse epididymis and testis fibrosis.

The invention discloses a reagent for rapidly distinguishing bacterial and virus infection and application, belongs to the field of molecular biology, relates to medical and biotechnology, and aims to solve the problem that a traditional method cannot clearly distinguish bacterial infection from virus infection. The reagent comprises five antibodies marked with different fluorescence. The five antibodies are all mouse anti-human or rabbit anti-human antibodies, and targets corresponding to the five antibodies are respectively CD45, CD14, CD64, CD169 and HLA-DR (human leukocyte antigen-DR). The tail end of the antibody is connected with different fluorescein through chemical reaction; fluorescence labeling is performed on neutrophils, mononuclear cells and lymphocytes in peripheral blood through an antibody combination of CD molecules, and corresponding infection indexes are calculated through a flow cytometry method, so that the infection type (bacterial / virus infection) of a patient is quickly distinguished and judged.

The invention provides an in-vitro skin blood vessel immune model as well as a preparation method and application thereof. THP-1 human monocyte leukemia cells are induced to be differentiated into M0 type macrophages, and then the M0 type macrophages are respectively induced into M1 type macrophages and / or M2 type macrophages; then co-culturing the M1 type and / or M2 type macrophages and vascular endothelial cells to form a vascular immune model; finally, the 3D skin model is placed on the blood vessel immune model, external stimulation is conducted, and the in-vitro skin blood vessel immune model is constructed. The in-vitro skin blood vessel immune model can be used for repairing skin barriers, inflammation pathways, blood vessel metabolism, the expression level of genes or proteins related to extracellular matrixes, vascular endothelial cells, the proliferation and migration ability of activated macrophages and the like. The seven feature dimensions of the physiological structure feature of the skin model are used for screening the to-be-tested sample and exploring the action mechanism, and the method has the characteristics of rapidness, multiple screening dimensions, high accuracy, low construction difficulty, low cost and high universality.

The invention provides a depression diagnosis marker which is selected from one or more of immune cell Trem1 classical mononuclear cells, B cells, CD36 mononuclear cells, HLADR mononuclear cells, Th17, Treg, cell factors CXCL14, VEGFR1IL-1, RII, RANK, XEDAR, GITR, CRTAM, IL-11, IGFBP-2 and Fetuin A. The depression diagnosis marker has high MDD curative effect prediction efficiency. The invention further discloses application of the depression diagnosis marker in preparation of products for diagnosing depression, and the depression diagnosis marker has high MDD diagnosis value.

A method for delivery of a nucleic acid. comprising administering a lipid nanoparticle composition loaded with the nucleic acid to a subject in which monocytes and / or macrophages have been depleted. thereby delivering the nucleic acid into the subject, the method may more particularly be practiced according to the following steps: a) depleting monocytes and / or macrophages in a subject: and b) administering a lipid nanoparticle composition loaded with the nucleic acid to the subject, thereby delivering the nucleic acid into the subject.

The invention provides an applicable population screening method and application of a glioma dry-like cell sensitized DC vaccine, peripheral blood of a patient before and after inoculation of the glioma dry-like cell sensitized DC vaccine is obtained, mononuclear cells are extracted, CD8 + T cells are respectively separated from the mononuclear cells through a magnetic bead sorting method, and the CD8 + T cells are separated from the mononuclear cells. The method comprises the following steps: uniformly inoculating CD8 < + > T cells into an ELISPOT cell culture plate coated with an IFN-gamma antibody for culture, respectively setting an experimental group and a positive control group for culture, adding A2B5 < + > glioma cell lysis buffer into the experimental group and adding phytohemagglutinin into the positive control group, and carrying out ELISPOT staining on the cultured cells to obtain the secretion amount of FN-gamma before and after treatment of a patient. According to the secretion amount of the FN-gamma, patients with specific immune response to the glioma dry-like cell sensitization DC vaccine are screened, so that the glioma dry-like cell sensitization DC vaccine is conveniently popularized and applied, and the immune mechanism of the glioma dry-like cell sensitization DC vaccine is researched.

The invention discloses an indirect ELISA (Enzyme-Linked Immunosorbent Assay) detection kit for distinguishing host infected Listeria monocytogenes and / or Listeria ivanovii. The coating antigens are respectively a recombinant listeria monocytogenes surface protein ActA, a serotype 4h listeria monocytogenes and listeria ivanovii common outer membrane protein SmcL and a listeria ivanovii specific outer membrane protein I-inlH, indirect ELISA methods are respectively established based on the three antigens, the three detection methods are combined to detect the content of the listeria monocytogenes, and the content of the listeria ivanovii can be detected. The levels of the ActA antibody, the SmcL antibody and the I-inlH antibody in a clinical serum sample can be effectively monitored, and the detection on the listeria monocytogenes caused by the listeria monocytogenes and / or the listeria ivanovii is realized. The kit is relatively high in sensitivity, strong in specificity and good in stability, and an effective method is provided for epidemiological investigation and diagnosis of listeria monocytogenes.

The invention belongs to the field of new application of medicines, and particularly relates to application of SIRT4-IN-1 in preparation of medicines for treating autoimmune diseases. It is found for the first time that SIRT4-IN-1 reduces the activation degree of immune response induced by HSV-1 virus infection by up-regulating acetylation modification of cGAS, inhibits abnormal activation of immune response in Trex1 deficient mouse cells and peripheral blood mononuclear cells of systemic lupus erythematosus patients, and improves abnormal activation of autoimmune response. The invention provides a new candidate drug for clinical treatment of systemic lupus erythematosus.

Provided herein are compositions, kits, and methods for manufacturing cells for adoptive cell therapy comprising engineered monocytes or engineered monocyte-derived macrophages that overexpress ID3 for the treatment of cancer.

The invention belongs to the technical field of biomedicine, and particularly relates to application of GPR161 as an acute distress syndrome diagnostic marker and a therapeutic target. Experiments prove that the expression level of GPR161 in peripheral blood mononuclear cells of a patient with the acute respiratory distress syndrome is remarkably increased, and the expression quantity of the GPR161 is positively correlated with the severity of the disease, so that the GPR161 gene or GPR161 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the acute respiratory distress syndrome; a reagent for inhibiting GPR161 gene expression or protein activity can be used for preparing a medicine for treating the acute respiratory distress syndrome. The invention provides a new strategy for diagnosis, monitoring and targeted drug development of ARDS, and has important clinical application value.

The invention discloses a monoluciferase-based ADCP biological activity detection method, which comprises the following steps: separating a mononuclear cell from a human peripheral blood mononuclear cell as an effector cell, phagocytizing a Raji cell transfected by Luciferase as a target cell by the mononuclear cell, acidifying and degrading the Raji cell in a phagocytic body, and degrading the Luciferase so as to attenuate a light-emitting signal, so that the ADCP biological activity is detected. The ADCP biological activity of the antibody therapeutic drug is accurately quantified by detecting the weakening of the light-emitting signal. According to the present invention, the method only needs to separate the mononuclear cells and perform Luciferase infection on the target cells, and only needs to add the luciferase substrate after the phagocytosis process, such that the luminescence value can be read by using the microplate reader, the operation process is simple, the steps are less, the time consumption is short, the high-throughput screening is achieved, and the new direction is provided for the ADCP detection.

The invention belongs to the technical field of microbiological detection, and discloses a method for realizing dual, rapid and portable detection of Listeria monocytogenes by integrating PfAgo cutting and LAMP amplification by virtue of a fluorescence and reverse fluorescence enhanced lateral flow technology, and the method is based on an Argonaute combined isothermal amplification detection technology, integrates a signal amplification system of PfAgo cutting and LAMP isothermal amplification, and realizes rapid and portable detection of Listeria monocytogenes by virtue of a fluorescence and reverse fluorescence enhanced lateral flow technology. And the reverse fluorescence lateral flow technology is combined, so that the listeria monocytogenes can be sensitively, selectively and accurately detected on site in a short time. According to the detection method based on the visual reverse fluorescence test strip, visual and reverse fluorescence mutual verification for rapid and ultra-sensitive detection and application of Listeria monocytogenes can be realized by combining visual colorimetry and a reverse fluorescence lateral flow technology, dependence on a large instrument is not needed, the cost is relatively low, the operation is simple and convenient, and the detection method can be applied to rapid and ultra-sensitive detection of Listeria monocytogenes. And portable on-site detection of the food-borne pathogenic bacteria can be realized.

This disclosure describes methods of and systems for screening for sepsis or septic shock in a patient and methods of ruling out sepsis or septic shock in a patient using white blood cell count (WBC), a monocyte cell population parameter, or neutrophil-to-lymphocyte ratio (NLR), or a combination thereof, in the blood sample from the patient.

According to one embodiment, an initialization agent is for initializing blood cells derived from peripheral blood. The initialization agent includes an initialization factor group for producing iPS cells by initializing a group of blood cells including mononuclear cells derived from peripheral blood, and a group of lipid nanoparticles that encapsulate the initialization factor group. The lipid nanoparticles have a component of at least or more of 40% FFT-10 and FFT-20. FFT-10 and FFT-20 are included in equal amounts.

The invention provides a mononuclear cell for treating sepsis cardiomyopathy, and also relates to application of the mononuclear cell in preparation of drugs for improving sepsis and sepsis cardiomyopathy. The mononuclear cell provided by the invention can have a better targeted enrichment characteristic, so that the effective rate of treatment is improved, and meanwhile, toxic and side effects caused by non-specific distribution of drugs are reduced. Besides, the mononuclear cells are derived from the body of a healthy body, so that the mononuclear cells are more stable in metabolism, higher in absorption efficiency and more excellent in enrichment effect when acting on the body, and the technical problems that in-vivo half-life period of drugs is short and catabolism is easy in the prior art are solved.

The invention discloses a gracilaria variegata low-molecular-weight polysaccharide GBP-1a, the monosaccharide is composed of 82.8% of galactose and 17.2% of glucose through structural analysis, the molecular weight of the uniform polysaccharide is 2887Da, and the polysaccharide has no toxicity to THP-1 mononuclear cells and THP-1 macrophages within a set concentration range through activity detection; and after the polysaccharide is subjected to immune training on THP-1 mononuclear cells and THP-1 macrophages, the immune response of the polysaccharide is obviously higher than that of cells which are not subjected to polysaccharide immune training, so that the training of the polysaccharide is preliminarily deduced to possibly enable the cells to generate acquired immunity similar to vaccines.

The invention provides a preparation method of DC cells. The preparation method is especially suitable for rapidly obtaining high-purity and high-functional-activity DC cells. The method comprises the steps of separation from peripheral blood mononuclear cells (PBMC), induction culture, maturation treatment and the like, maturation of the dendritic cells is promoted by introducing an anti-CD47 single-domain antibody or LPS, and the immunocompetence of the dendritic cells is remarkably improved. The method is further applied to preparation of an anti-tumor cell preparation, the capability of activating tumor specific T cells by tumor antigen-loaded DC cells can be remarkably enhanced, and the killing activity of the T cells to tumor cells is improved. The preparation method provided by the invention overcomes the defects in the prior art, has the advantages of high efficiency, safety and stability, and can provide a more reliable cell therapy scheme for tumor immunotherapy.

The invention discloses a biomarker for predicting the prognosis condition of sepsis and application, and belongs to the technical field of biology. The biomarkers comprise a ratio of neutrophils to lymphocytes, a ratio of platelets to lymphocytes, a ratio of monocytes to lymphocytes, a ratio of leukocytes to lymphocytes, a system inflammatory response index and a peripheral inflammatory value. According to the method, the ratio of neutrophil to lymphocyte, the ratio of platelet to lymphocyte, the ratio of mononuclear cell to lymphocyte, the ratio of leukocyte to lymphocyte, a systemic inflammatory response index and a peripheral inflammatory value are utilized to carry out accurate prognosis risk stratification on the sepsis patient, and prognosis survival risk prediction is carried out on the sepsis patient; the accuracy and timeliness of prognosis evaluation of sepsis patients are remarkably improved, a reliable guidance basis is provided for clinical decision making, and the method has important clinical application value and popularization significance.

The invention belongs to the technical field of food microorganisms, and particularly relates to an enterococcus lactis NSK220 strain, a microbial agent and application of the enterococcus lactis NSK220 strain. The invention provides the enterococcus faecium NSK220, the clearance rate of the enterococcus faecium NSK220 on DPPH is very high, the serum SOD enzyme activity can be improved by supplementing the strain NSK220 in diet, and it is indicated that the oxidation resistance of the strain NSK220 is high. Meanwhile, the enterococcus faecium NSK220 has relatively strong self-cohesion and surface hydrophobicity, which indicates that the strain has strong colonization ability and is beneficial to long-term play of probiotic functions in intestinal tracts; the strain NSK220 can also improve the feed intake and kidney function of animals, and is beneficial to the growth and body health of the animals. The enterococcus faecium NSK220 has an inhibition effect on escherichia coli, staphylococcus aureus, salmonella, pseudomonas aeruginosa and listeria monocytogenes.

The invention discloses a biomarker for diagnosing systemic lupus erythematosus and lupus nephritis and application of the biomarker, and relates to the technical field of biological medicines. The biomarker is an ISG15hiCD16 < + > mononuclear cell. According to the application disclosed by the invention, the ISG15hiCD16 + mononuclear cell subpopulation is found to be obviously increased in an SLE (systemic lupus erythematosus) patient. The invention also finds that the expression level of the ISG15hiCD16 + mononuclear cell subpopulation is positively correlated with the disease activity of the SLE patient, and the expression level of the ISG15hiCD16 + mononuclear cell subpopulation of the SLE patient with the kidney enduring expression is obviously higher than that of the SLE patient without the kidney enduring expression. The working characteristic curve analysis of a subject shows that the ISG15hiCD16 + mononuclear cell subset has better sensitivity and specificity for diagnosing the SLE and the LN, and has important significance for clinical auxiliary diagnosis of the SLE and the LN and illness state evaluation.

The present invention relates to vaccines based on viral vectors for delivery of antigens against infectious diseases. In particular, the present invention relates to a recombinantly modified vaccinia virus Ankara (MVA) encoding EBV antigens that elicit infectious mononuclear hyperplasia (IM) and different cancer types. The invention also relates to medical application of the recombinant MVA in prevention of diseases caused by EBV (Epstein-Barr Virus).

The invention belongs to the technical field of immunology, and particularly discloses an in-vitro preparation method and application of an induced follicular regulatory T cell iTfr.The in-vitro preparation method comprises the steps that mouse spleen single-cell suspension or healthy human peripheral blood is obtained, peripheral blood mononuclear cells are obtained, then initial CD4 + T cells are obtained through immunomagnetic bead sorting, and iTfr cells are obtained; then carrying out induced differentiation by using an antibody and a specific cytokine, and carrying out continuous stimulation and culture by adopting two different cytokine polarization conditions, so as to obtain the iTfr cell. The invention provides a method for preparing the iTfr cells in vitro, which is expected to obtain an enough number of induced follicular regulatory T cells, and provides an important tool and a treatment means for in vitro research of immune tolerance related diseases such as autoimmune diseases and organ transplantation.

This invention provides a tetrahedral antibody comprising a first domain, a second domain, a third domain, a fourth, a fifth domain, and a sixth domain, wherein the first domain and the second domain are each a Fc domain of an IgG antibody, wherein the third domain and the fourth domain are each a Fab domain of an anti-CD20 antibody wherein the fifth domain and the sixth domain are each a Fab domain of an anti-CD-19 antibody. This invention also provides methods of producing the tetrahedral antibody of the invention, pharmaceutical compositions comprising the tetrahedral antibody of the invention, and methods of treating B cell cancer, inflammatory disease, and B cell disease by administering the pharmaceutical compositions of the invention.

The invention belongs to the technical field of biology, and particularly relates to application of a biomarker BIG1 to preparation of a reagent for diagnosing or monitoring sepsis immunosuppression. According to the invention, BIG1 expression in peripheral blood mononuclear cells is used as a biomarker to prepare a reagent for predicting sepsis immunosuppression, and by detecting the transcription or translation level of BIG1 in peripheral blood mononuclear cells or tissue macrophages, expression reduction indicates immune activation of sepsis patients, and expression increase indicates immunosuppression of sepsis patients. Therefore, individualized precise intervention treatment can be properly given, the treatment rate of sepsis is increased, reference information is provided for reasonable selection of treatment means and allocation of medical resources, and the method has important clinical application value in improvement of prognosis of sepsis patients.

Hematopoietic stem cells (HSC) are essential to developing a functional immune system, including monocyte-macrophage cells required for wound healing. Described herein are methods of using yellow bone marrow as a source of cells to generate hematopoietic stem cells. The methods include expansion of human hematopoietic stem cells by culture of human yellow bone marrow in 3-dimensional hydrogel and pro-angiogenic, stem cell-promoting medium.

The invention provides a composition for promoting differentiation of intestinal immune cells as well as a preparation method and application of the composition. According to the composition, 1, 3-dioleic acid-2-palmitic acid triglyceride and breast milk oligosaccharide are used in a combined manner, so that monocytes can be effectively promoted to differentiate into intestinal macrophages, and inflammation is reduced to a certain extent. After the monocytes are differentiated into the intestinal macrophages, the intestinal immune homeostasis and intestinal microbiota inflammatory response can be regulated, so that the mucosal immune homeostasis and intestinal epithelial cell barrier function are maintained. Therefore, the composition provided by the invention can improve the intestinal immune barrier by promoting the monocytes to differentiate into the intestinal macrophages, and provides a new thought for improving the early intestinal barrier of infants through nutritional supplement.